Ongoing 2b/3a inhibition In Myocardial infarction Evaluation.

Possible other participating centres: br>
The Netherlands:

UMCG Groningen, Dpt of Cardiology, Dr. F. Zijlstra, MD, PhD.;

Germany:

Klinikum Schweinfurt, Dpt of Cardiology, Prof. Seggewiss;

Klinikum Coburg, Dpt of Cardiology, Prof. Brachmann;

Städstische Kliniken a.N. Esslingen, Dpt od Cardiologie, Prof. Leschke;

Herzzentrum Bad Krozingen, Prof. Neumann;

Klinikum Lüdenscheid. Dpt of Cardiology, Dr. Lemke, MD, PhD;

Klinikum Krefeld, Dpt of Cardiology, Prof. Späh;

Evangelisches Krankenhaus Düsseldorf, Dpt of Cardiology, Prof. Vester;

Kliniken der Ruhr-Universität Bochum, Dpt Cardiology, Prof. Mügge;

Essener Herzinfarktverbund, 4 Essener Kliniken;

Der Charité - Universitätsmedizin Berlin, Dpt of Cardiology, Dr. Möckel MD, PhD. (Dr. Dwäre MD, PHD.);

Städtisches Klinikum Kiel, Dpt of Cardiology, Prof. Buchwald;

Universitätsklinikum Lübeck, Dpt of Cardiology, Prof. Schunkert;

Herzzentrum Brandenburg in Bernau, Dr. Butter, MD, PhD;

Universitätsklinikum Röstock, Dpt of Cardiology, Prof. Nienaber;

Belgium:

CHR de la Citadelle Liège, Dpt of Cardiology, Dr. Jean Boland;

Poland:

University Hospital Poznan, Dpt of Cardiology, Dr. Lesiak, MD, PhD;

Primary:

Upfront pre-treatment with a high bolus dosage of Tirofiban will result in a lower extent of residual ST segment deviation 1 hour after Primary Coronary Angioplasty for acute myocardial infarction, compared to no pre-treatment (besides Aspirin, Heparin and 600 mg of Clopidogrel).




Secondary:

1. Upfront pre-treatment with a high bolus dosage of Tirofiban will result in a higher incidence of TIMI 3 flow of the infarct related vessel (IRV) at initial angiography, compared to no pre-treatment (besides Aspirin, Heparin and 600 mg of Clopidogrel).

2. Upfront pre-treatment with a high bolus dosage of Tirofiban will result in a higher incidence of normal myocardial perfusion as assessed by Myocardial Blush Grade scoring on immediately after primary angioplasty, compared to no pre-treatment (besides Aspirin, Heparin and 600 mg of Clopidogrel).

3. Upfront pre-treatment with a high bolus dosage of Tirofiban will result in a smaller infarct size as assessed by a single cTnT measurement performed 48-72 hours after Primary Coronary Angioplasty for acute myocardial infarction, compared to no pre-treatment (besides Aspirin, Heparin and 600 mg of Clopidogrel).

4. Upfront pre-treatment with a high bolus dosage of Tirofiban will result in a lower incidence of the combined occurrence of death, recurrent MI, urgent TVR or thrombotic bailout at 30 days follow-up, compared to no pre-treatment (besides Aspirin, Heparin and 600 mg of Clopidogrel).

5. Upfront pre-treatment with a high bolus dosage of Tirofiban will not result in a higher incidence of major bleeding (according to the most recent TIMI criteria), compared to no pre-treatment (besides Aspirin, Heparin and 600 mg of Clopidogrel).

N/A

1. Pre-treatment with a high bolus dosage of Tirofiban (25 ìg/kg bolus);

2. No pre-treatment (besides Aspirin, Heparin and 600 mg of Clopidogrel).